Aspirin for primary prevention: time to reconcile discrepancies - Takeaways - MDSpire

Aspirin for primary prevention: time to reconcile discrepancies

  • By

  • Matteo Mazzola

  • Raffaele De Caterina

  • September 3, 2025

  • 0 min

Share

  • 1

    Aspirin's role in primary prevention of cardiovascular disease has been questioned due to inconsistent trial results and potential bleeding risks.

  • 2

    Recent analyses suggest aspirin may benefit individuals with a calculated cardiovascular risk exceeding 20/100 patients at 10 years.

  • 3

    The relationship between cardiovascular risk and aspirin's protective effects against major adverse cardiovascular events is significant.

  • 4

    Shared decision-making is essential when considering aspirin for primary prevention, emphasizing lifestyle measures and risk management.

  • 5

    Aspirin may still be appropriate for high-risk patients without overt atherosclerosis, challenging the strict boundaries of prevention categories.

Original Source(s)

Aspirin for primary prevention: time to reconcile discrepancies

  • by Matteo Mazzola, Raffaele De Caterina

  • September 3, 2025

Related Content

An explainable streaming early identification model for early neurological deterioration based on coordinated fusion of ECG waveforms and vital signs

The immune-endothelial axis in neurovascular pathophysiology: a framework for targeted interventions

Diabetes Risk Scores: Beyond Glucose

Multi-ancestry polygenic models identify high-risk patients traditional screening may miss.